{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:55Z","timestamp":1790742055103,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,25]]},"DOI":"10.7759\/cureus.81134","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T09:30:48Z","timestamp":1742895048000},"source":"Crossref","is-referenced-by-count":1,"title":["Dose Adjustments of Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria Undergoing Surgery: A Case Report"],"prefix":"10.7759","author":[{"given":"Miriam","family":"Vara Pampliega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Arzuaga-Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Moreno Gamiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.2.214","article-title":"Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH Registry","volume":"31","author":"Jang JH","year":"2016","unstructured":"Jang JH, Kim JS, Yoon SS, et al.. Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH Registry. J Korean Med Sci. 2016, 31:214-21. 10.3346\/jkms.2016.31.2.214","journal-title":"J Korean Med Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16271","article-title":"Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment","volume":"132","author":"Szlendak U","year":"2022","unstructured":"Szlendak U, Budziszewska B, Spychalska J, Drozd-Soko\u0142owska J, Patkowska E, Nowak J. Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment. Pol Arch Intern Med. 2022, 132:10.20452\/pamw.16271","journal-title":"Pol Arch Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26832","article-title":"Paroxysmal nocturnal hemoglobinuria: where we stand","volume":"98 Suppl 4","author":"Panse J","year":"2023","unstructured":"Panse J. Paroxysmal nocturnal hemoglobinuria: where we stand. Am J Hematol. 2023, 98 Suppl 4:S20-32. 10.1002\/ajh.26832","journal-title":"Am J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2022.01.001","article-title":"Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress","volume":"59","author":"Peffault de Latour R","year":"2022","unstructured":"Peffault de Latour R, Hosokawa K, Risitano AM. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress. Semin Hematol. 2022, 59:38-46. 10.1053\/j.seminhematol.2022.01.001","journal-title":"Semin Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi M","year":"2016","unstructured":"Loschi M, Porcher R, Barraco F, et al.. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol. 2016, 91:366-70. 10.1002\/ajh.24278","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236877","article-title":"Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Brodsky RA","year":"2021","unstructured":"Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al.. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021, 106:230-7. 10.3324\/haematol.2019.236877","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00210-1","article-title":"Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial","volume":"9","author":"de Latour RP","year":"2022","unstructured":"de Latour RP, Szer J, Weitz IC, et al.. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022, 9:e648-59. 10.1016\/S2352-3026(22)00210-1","journal-title":"Lancet Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen P","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, et al.. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021, 384:1028-37. 10.1056\/NEJMoa2029073","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2201664","article-title":"Breakthrough hemolysis in PNH with proximal or terminal complement inhibition","volume":"387","author":"Notaro R","year":"2022","unstructured":"Notaro R, Luzzatto L. Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. N Engl J Med. 2022, 387:160-6. 10.1056\/NEJMra2201664","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0009","article-title":"Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)","volume":"102","author":"Hall C","year":"2003","unstructured":"Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003, 102:3587-91. 10.1182\/blood-2003-01-0009","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011691","article-title":"Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH","volume":"8","author":"Griffin M","year":"2024","unstructured":"Griffin M, Kelly RJ, Panse J, et al.. Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH. Blood Adv. 2024, 8:1776-86. 10.1182\/bloodadvances.2023011691","journal-title":"Blood Adv"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen P","year":"1995","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995, 333:1253-8. 10.1056\/NEJM199511093331904","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly RJ","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, et al.. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011, 117:6786-92. 10.1182\/blood-2011-02-333997","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27242","article-title":"Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Griffin M","year":"2024","unstructured":"Griffin M, Kelly R, Brindel I, et al.. Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2024, 99:816-23. 10.1002\/ajh.27242","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009129","article-title":"Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria","volume":"7","author":"Wong RS","year":"2023","unstructured":"Wong RS, Navarro-Cabrera JR, Comia NS, et al.. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2023, 7:2468-78. 10.1182\/bloodadvances.2022009129","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/342328-dose-adjustments-of-pegcetacoplan-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-undergoing-surgery-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T09:30:50Z","timestamp":1742895050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/342328-dose-adjustments-of-pegcetacoplan-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-undergoing-surgery-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.81134","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}